Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard, J&J Settle Mesh Cases

This article was originally published in The Gray Sheet

Executive Summary

CR Bard has settled 150 pelvic mesh claims against the company in West Virginia, while Ethicon paid $5 million to resolve one in New Jersey. An industry observer believes this is part of a trend.

You may also be interested in...

Jury Awards Plaintiff $68M In Bard Mesh Case

CR Bard has lost the first transvaginal mesh case to be tried in New Jersey, but there are another 150 to go in the state. A Bergen County jury awarded $33m in compensatory damages and $35m in punitive damages to a woman who says she's experienced chronic pain and other complications since receiving two of the company's transvaginal mesh products in 2009.

Court Rules Against Ethicon In Pelvic Mesh Case, But Without Punitive Damages

A jury awarded $2.16 million in the case, making it the first time a jury in a pelvic mesh case has ruled in a plaintiff’s favor without including punitive damages. Meanwhile, Ethicon is also appealing an earlier case to the US Supreme Court, and CR Bard has settled almost 100 pelvic mesh cases pending in West Virginia.

Number to Know …37,724

A total of 37,724 women have filed suit against Johnson & Johnson-subsidiary Ethicon Endo-Surgery in ongoing multi-district litigation being heard in the Southern District of West Virginia. The women say they were injured by the company’s pelvic mesh products.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts